Last reviewed · How we verify
Diluted Deodorized Tincture of Opium
Diluted Deodorized Tincture of Opium (DDO) is an opioid preparation that binds to opioid receptors in the central and peripheral nervous system to produce analgesia and antidiarrheal effects.
Diluted Deodorized Tincture of Opium (DDO) is an opioid preparation that binds to opioid receptors in the central and peripheral nervous system to produce analgesia and antidiarrheal effects. Used for Diarrhea management, Pain relief.
At a glance
| Generic name | Diluted Deodorized Tincture of Opium |
|---|---|
| Also known as | Laudanum |
| Sponsor | Eastern Maine Medical Center |
| Drug class | Opioid agonist |
| Target | Mu opioid receptor (primary), delta opioid receptor, kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management, Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
DDO contains alkaloids from opium poppies, primarily morphine, which act as agonists at mu, delta, and kappa opioid receptors. This receptor activation reduces pain perception and decreases gastrointestinal motility. The deodorized formulation removes volatile compounds while retaining the active opioid alkaloids, making it suitable for oral administration in clinical settings.
Approved indications
- Diarrhea management
- Pain relief
Common side effects
- Constipation
- Drowsiness
- Nausea
- Respiratory depression
- Dependence potential
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: